Lindbrook Capital’s Regenxbio RGNX Stock Holding History

Lindbrook Capital’s Portfolio RGNX Stock Details RGNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	$1.09K	Buy	+153	New	+$1.14K	﹤0.01%	2434
2024 Q1	–	Sell	-87	Closed	-$1.56K	–	2739
2023 Q4	$1.56K	Buy	+87	New	+$1.53K	﹤0.01%	2345
2022 Q2	–	Sell	-99	Closed	-$3K	–	2721
2022 Q1	$3K	Sell	99 -51	-34%	-$1.42K	﹤0.01%	1866
2021 Q4	$5K	Buy	150 +64	+74%	+$2.18K	﹤0.01%	1524
2021 Q3	$4K	Buy	86 +50	+139%	+$1.8K	﹤0.01%	1341
2021 Q2	$1K	Hold	36	–	–	﹤0.01%	1811
2021 Q1	$1K	Hold	36	–	–	﹤0.01%	1779
2020 Q4	$2K	Buy	+36	New	+$1.26K	﹤0.01%	1497
2019 Q1	–	Sell	-200	Closed	-$8K	–	1488
2018 Q4	$8K	Buy	+200	New	+$11.7K	﹤0.01%	894

Other funds holding RGNX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Lindbrook Capital's RGNX Position: Q1 2025 in Review

Lindbrook Capital opened a new position in Regenxbio (RGNX) in Q1 2025: 153 shares worth $1.09K. The stake represents ﹤0.01% of the portfolio and ranks #2434 among its holdings. This is a return to the name: Lindbrook Capital previously reported a position in RGNX as recently as Q4 2023.

Lindbrook Capital first reported a position in RGNX in Q4 2018 and has held it in 9 quarters since. The position peaked at $8K in Q4 2018. 164 funds tracked by Wall St. Rank hold RGNX as of Q1 2025.

Lindbrook Capital held 153 shares of Regenxbio worth $1.09K as of Q1 2025.
Regenxbio was a new Lindbrook Capital position in Q1 2025.
Regenxbio made up ﹤0.01% of Lindbrook Capital's portfolio in Q1 2025, its #2434 holding.
Lindbrook Capital first reported a position in Regenxbio in Q4 2018 and has held it in 9 quarters since.
Lindbrook Capital's Regenxbio position peaked at $8K in Q4 2018.
164 funds tracked by Wall St. Rank held Regenxbio as of Q1 2025.

Based on Lindbrook Capital's 13F filing for Q1 2025, filed 5 May 2025.